Cabio Biotech (Wuhan) Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 166.76 million compared to CNY 163.11 million a year ago. Revenue was CNY 171.15 million compared to CNY 163.11 million a year ago.

Net income was CNY 50.02 million compared to CNY 67.57 million a year ago. Basic earnings per share from continuing operations was CNY 0.3 compared to CNY 0.4 a year ago. Diluted earnings per share from continuing operations was CNY 0.3 compared to CNY 0.4 a year ago.